drug,indication,aware,adult_dose,renal_thr,renal_dose_lt_thr,route,notes,refs
Cefepime (IV),HAP/VAP (incl. P. aeruginosa risk),Watch,2 g IV every 8 h; infuse over ~30 min,CrCl<=60 mL/min: adjust,CrCl 30–60: 2 g q24h; 11–29: 1 g q24h; <11: 500 mg q24h; HD: 1 g day 1 then 500 mg q24h (post-HD),IV,Use higher dose for P. aeruginosa; monitor neurotoxicity esp. in renal impairment,FDA Cefepime label 07/2025 Table 1–2; WHO AWaRe 2023
Piperacillin–Tazobactam (IV),Nosocomial pneumonia (initial empiric),Watch,4.5 g IV every 6 h + aminoglycoside (if P. aeruginosa suspected),CrCl<=40 mL/min: adjust,CrCl 20–40: 3.375 g q6h; <20: 2.25 g q6–8h; HD: 2.25 g q8h with +0.75 g post-HD,IV,Infuse over 30 min; continue aminoglycoside if P. aeruginosa isolated,FDA Zosyn label 12/2024 Table 1
Amoxicillin–Clavulanate (PO),AECOPD with bacterial features (outpatient),Access,875/125 mg PO every 12 h for 5–7 days (example regimen; follow local resistance),CrCl<30 mL/min: avoid 875 mg strength; adjust interval,CrCl 10–30: 500/125 mg q12h; <10: 500/125 mg q24h (example from common references—verify local label),PO,"Antibiotics only when bacterial signs (e.g., ↑sputum purulence/volume or ventilation need) per GOLD",GOLD 2025 report (abx indications); WHO AWaRe 2023
